20:30 , Jan 13, 2017 |  BC Week In Review  |  Company News

Selten, Vivus deal

Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary arterial hypertension (PAH) and related vascular diseases. Selten had rights to patents covering the drugs from Stanford University (Stanford,...
07:00 , Aug 10, 2015 |  BioCentury  |  Emerging Company Profile

New tac for modifying PAH

Selten Pharma Inc. is developing a new formulation of the generic immunosuppressive drug tacrolimus that activates the BMPRII pathway and could prevent or even reverse the deleterious vascular remodeling seen with pulmonary arterial hypertension. In...
07:00 , Jul 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Bone morphogenetic protein 9 (BMP9; GDF2); bone morphogenetic protein receptor type II (BMPRII)

Cardiovascular disease INDICATION: Hypertension Cell culture and mouse studies suggest BMP9 could help treat pulmonary arterial hypertension (PAH). Mutations in BMPRII have been associated with PAH pathogenesis. In assays in endothelial cells from PAH patients...
07:00 , Jul 14, 2011 |  BC Innovations  |  Targets & Mechanisms

NOGO could go far

A team of U.S. and Canadian researchers has shown that blocking production of NOGO-B in pulmonary arteries could prevent the deleterious vascular remodeling seen in pulmonary arterial hypertension. 1 If future studies demonstrate that NOGO-B...